With global central banks holding policy rates high as inflation pressures linger, cash in the bank can feel stuck while prices keep rising. Reliable dividends over 5% start to look more appealing when income is hard to grow through interest alone. This article walks through three dividend powerhouses from the 3%+ Yield screener that combine higher yields with coverage and stability to help anchor a long term portfolio.
The three stocks in this article are just a starting sample, and the full screen surfaced 28 more companies with equally compelling dividend stories that are not covered here. To identify and analyze those high yield opportunities for yourself, head straight into the Dividend Powerhouses (3%+ Yield) screener.
Overview: CSL is a global biopharmaceutical company that turns donated human plasma into medicines for serious immune and blood disorders, produces flu vaccines for governments, and supplies treatments for iron deficiency and kidney disease across major markets including the United States, Europe, China, and Australia.
Operations: CSL generates most of its revenue from CSL Behring at about US$10.9b, with additional contributions from CSL Vifor at about US$2.4b and CSL Seqirus at about US$2.2b.
Market Cap: A$63.4b
CSL may be of interest if you want dividend income from a healthcare company with a long operating history and are comfortable with some short term noise. The core plasma and vaccine businesses remain central to patients with rare conditions, yet the stock reflects pressure from a recent restructuring, a large one off loss of US$2.1b, higher debt and a lower net margin of 9.1%. At the same time, analysts currently forecast earnings growth, the company is advancing new therapies like ANDEMBRY for hereditary angioedema, and management is targeting sizeable cost savings. For investors willing to look past the clean up period, the mix of income, defensiveness and the potential for an earnings recovery makes CSL an intriguing candidate from this high yield screen.
CSL’s earnings recovery story is easy to miss when attention sits on that US$2.1b loss and higher debt. Get the full picture on income strength, cost saves and hidden pressure points in the 2 key rewards and 4 important warning signs
CSL and the other stocks in this article all came out of a single screener, but the real value for you is in shaping your own filters. Use our flexible Screener to blend metrics like dividends, balance sheet strength and risks into a watchlist that fits your approach, or start with one of our curated Investing Ideas.
Overview: QBE Insurance Group is a global general insurer that covers everything from homes, cars and farms through to commercial property, workers’ compensation, cyber and specialty risks, while also running a reinsurance business and managing Lloyd’s syndicates from its base in Sydney.
Operations: QBE generates most of its revenue from International at about US$11.2b, followed by North America at about US$8.2b, Australia Pacific at about US$5.7b and a small contribution from Corporate & Other.
Market Cap: A$36.4b
QBE Insurance Group offers a combination that yield seekers often look for but rarely find in one place: global diversification, solid profitability and exposure to growing areas like cyber cover, all backed by an A rated balance sheet and an 18.5% return on equity. The company has been trimming its capital stack, with recent redemptions of subordinated notes, and AM Best reaffirmed its Excellent credit ratings in late July 2026. The trade off is real. Premium rate pressure, volatile large losses and an uneven dividend history mean earnings and payouts can be bumpy. For investors comfortable with insurance cycles, that mix of quality, risks and a potentially undervalued stock could warrant closer consideration.
QBE Insurance Group’s A rated balance sheet and 18.5% return on equity suggest that the market may be overlooking aspects of this insurance story. See how earnings volatility, dividend history and valuation all connect in the analysis report for QBE Insurance Group
Overview: Evolution Mining is an Australian based gold producer that explores for, develops and operates gold and gold copper mines in Australia and Canada, while also holding interests in copper, silver and lithium focused projects.
Operations: Evolution Mining generates most of its revenue from the Cowal asset at about A$1.7b and Ernest Henry at about A$1.1b, with further contributions from Mungari at about A$780 million, Red Lake at about A$670 million, Northparkes at about A$580 million and smaller amounts from Mt Rawdon and Corporate.
Market Cap: A$26.4b
Evolution Mining stands out in this dividend focused screen because it combines gold exposure with copper and lithium projects, while still delivering a 23.6% return on equity and net profit margins around 26%. Recent moves into the Greater Duchess copper gold project and the Nevada North lithium joint venture provide more than a pure gold focus, which can help margins hold up if gold sentiment changes. The stock trades on a relatively richer P/E ratio and depends on cost control in the context of rising labor and ESG related expenses. For income focused investors who are weighing valuation risk against diversification and current earnings metrics, there is more to consider beneath the surface of Evolution Mining’s headline yield.
Evolution Mining’s high 23.6% return on equity and 26% margins suggest more is going on beneath the surface than a simple gold story. See how copper, lithium and costs all fit together in the analysis report for Evolution Mining
Dividend stocks like CSL, QBE Insurance Group and Evolution Mining are just one angle. Fresh ideas can start breaking out or dropping fast. Do not get caught watching. Consider reviewing options early instead.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com